High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma
High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma
复制标题
高基线总病变糖酵解预测高肿瘤负荷滤泡性淋巴瘤患者 24 个月内疾病的早期进展
DOI：
10.1007/s12185-022-03418-5
复制
发表时间：
2022
影响因子：
2.1
通讯作者：
Naoto Takahashi
中科院分区：
文献类型：
--
作者：
Wataru Kuroki;Akihiro Kitadate;Koichi Ishiyama;Yoshihiro Kameoka;Naoto Takahashi
尽管引入了包含利妥昔单抗的方案，但大约20%的滤泡性淋巴瘤(FL)患者仍在24个月内经历疾病进展(POD24)，总体存活率较低。因此，需要一种更准确的风险评估工具。我们对45例接受18F-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(PET/CT)的高肿瘤负荷FL患者进行了基线18F-脱氧葡萄糖正电子发射断层扫描(PET/CT)、基线总代谢肿瘤体积(TMTV)和总病变糖酵解(TLG)两个新的基于体积的参数的预测价值。我们观察到，高TMTV、高TLG和较差的初始治疗反应(在诱导治疗结束时低于完全[代谢]反应[非CR/CMR])独立地预测较差的PFS。值得注意的是，POD24阳性患者在高TLG组比高TMTV组更常见，这表明TLG比TMTV是更强的预后预测因子。结合基线TLG和初始治疗反应显示，高TLG和非CR/CMR患者的预后明显较差，2年后无并发症发生率为0%(风险比60.39，P= 0.000002)。这一组合对检测将经历POD24的患者具有56%的敏感性和100%的特异性。基线TLG和初始治疗反应可以准确地识别POD24的高危患者。
Despite the introduction of rituximab-containing regimens, approximately 20% of patients with follicular lymphoma (FL) still experience progression of disease within 24 months (POD24) and have poor overall survival. Therefore, a more accurate risk assessment tool is required. We investigated the predictive value of two new volume-based parameters determined from baseline 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), baseline total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG), in 45 patients with high-tumor-burden FL who underwent baseline PET/CT. We observed that high TMTV, high TLG, and poor initial treatment response (less than complete [metabolic] response [non-CR/CMR] at the end of induction therapy) independently predicted poor PFS. Notably, POD24-positive patients were more common in the high-TLG group than in the high-TMTV group, which suggests that TLG is a stronger predictor of outcomes than TMTV. Combining baseline TLG and initial treatment response showed that patients with both high TLG and non-CR/CMR experienced significantly poorer outcomes, with a 2 year PFS of 0% (hazard ratio 60.39,P= 0.000002). This combination had 56% sensitivity and 100% specificity for detecting patients who would experience POD24. Baseline TLG and initial treatment response can precisely identify patients at high risk of POD24.
登录
查看更多内容
基于利妥昔单抗的生物双重前期治疗后滤泡性淋巴瘤的早期复发与死亡风险增加相关：CALGB 研究 50402、50701 和 50803（联盟）的综合分析
影响因子：
20.3
作者：
F. Lansigan;I. Barak;B. Pitcher;Sin;B. Cheson;M. Czuczman;B. Grant;P. Martin;E. Hsi;H. Schöder;Scott E. Smith;N. Bartlett;J. Leonard;K. Blum
通讯作者：
K. Blum
影响因子：
20.3
作者：
Freeman, Ciara L.;Kridel, Robert;Sehnt, Laurie H.
通讯作者：
Sehnt, Laurie H.
影响因子：
20.3
作者：
Cottereau, Anne Segolene;Versari, Annibale;Meignan, Michel
通讯作者：
Meignan, Michel
影响因子：
45.3
作者：
Casulo, Carla;Byrtek, Michelle;Friedberg, Jonathan W.
通讯作者：
Friedberg, Jonathan W.